NCT05014607

Personalized Multi-peptide Vaccination in Combination With the TLR1/2 Ligand XS15 in Cancer Patients

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: University Hospital Tuebingen · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

The aim of this project is to provide personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 to individual patients with advanced solid and hematological malignancies without any approved treatment options.

Detailed description

Ethics: Patient treatment will be conducted according to §13 Absatz 2b, AMG.

Conditions

• Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Personalized multi-peptide vaccine	Peptide vaccine: Personalized multi-peptide vaccine cocktails consisting of 200-300µg each of 1-10 tumor-associated peptides selected individually based on the patient-individual HLA allotypes and HLA ligandome analysis of tumor cells Peptides are synthesized in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen and will be formulated at the GMP-Center of the University Hospital Tübingen. Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant. Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned. Treatment schedule: Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned, depended on the induction of peptide-specific T-cell responses.

Timeline

• First posted: 2021-08-20
• Last updated: 2024-05-09